The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Collagen, the body's most abundant protein, has long been viewed as a predictable structural component of tissues. However, a new study challenges that notion, revealing an unexpected confirmation in ...

Ibogaine—a psychoactive plant derivative—has attracted attention for its anti-addictive and anti-depressant properties. But ...

A research team has developed a revolutionary two-dimensional polyaniline (2DPANI) crystal that overcomes major conductivity ...

Ibogaine — a psychoactive plant derivative — has attracted attention for its anti-addictive and anti-depressant properties.

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

The Department of Defense is funding research being carried out by the Larner College of Medicine and UVM Medical Center into ...

The lights dimmed as five actors took their places around a table on a makeshift stage in a New York City art gallery turned ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

Ketamine-assisted psychotherapy (KAP) uses low doses of ketamine alongside psychotherapy to treat mental health conditions.

EEG was essential in assessing the drug’s ketamine-like antidepressant effects on the brain. The second paper, entitled "Evaluating an EEG-based tool for assessing acute clinical and cognitive changes ...